Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v2.4.0.8
Commitments and Contingencies (Details) (Abbott Biotherapeutics Corp [Member], USD $)
3 Months Ended
Mar. 31, 2014
Phase I Clinical Trial of a licensed product [Member]
 
Summary of milestone payment  
Milestones payments $ 750,000
Phase II Clinical Trial of a licensed product [Member]
 
Summary of milestone payment  
Milestones payments 750,000
Phase III Clinical Trial of a licensed product [Member]
 
Summary of milestone payment  
Milestones payments 1,500,000
Biological License Application filing with U.S. FDA [Member]
 
Summary of milestone payment  
Milestones payments 1,750,000
First Commercial Sale [Member]
 
Summary of milestone payment  
Milestones payments 1,500,000
After First Net Sales [Member]
 
Summary of milestone payment  
Milestones payments $ 1,500,000